Open Access Research article

GOLPH2 expression in renal cell cancer

Florian Rudolf Fritzsche1, Mark-Oliver Riener1, Manfred Dietel3, Holger Moch1, Klaus Jung2 and Glen Kristiansen1*

Author Affiliations

1 Institute of Surgical Pathology, UniversitätsSpital Zürich, Zurich, Switzerland

2 Berlin Institute for Urologic Research, Berlin, Germany

3 Institute of Pathology, Charité – Universitätsmedizin Berlin, Berlin, Germany

For all author emails, please log on.

BMC Urology 2008, 8:15  doi:10.1186/1471-2490-8-15

Published: 11 November 2008



Renal cell carcinomas (RCC) are among the most common and most lethal genitourinary malignancies. GOLPH2 (golgi phosphoprotein 2, GOLM1) has recently been proposed as a biomarker for hepatocellular and prostate cancer. In this study we analysed the expression patterns and the prognostic and diagnostic value of GOLPH2 in RCC.


GOLPH2 protein expression was analysed by immunohistochemistry in 104 clinically well characterized RCC cases in comparison with matched normal kidney tissue and in association with clinico-pathological parameters. Statistical analyses including Kaplan Meier analyses were performed with SPSS version 15.0.


GOLPH2 was highly expressed in normal renal tubules and in almost half of RCC with a statistically significant predominance in the papillary and chromophobe histological subtypes. No other associations with clinico-pathological parameters were detectable. The Kaplan-Meier curves showed a weak trend for unfavourable prognosis of tumours with high GOLPH2 expression, but failed significance.


GOLPH2 protein is expressed in normal renal tissue (especially in distal tubular epithelia) and is down-regulated in the majority of clear cell RCC. In papillary and chromophobe RCC GOLPH2 expression is consistently present. In contrast to its diagnostic value in hepatocellular and prostatic carcinomas, a prognostic or diagnostic value of GOLPH2 in RCC appears to be unlikely.